 Outlook Therapeutics NASDAQ:OTLK Inc has ended the fiscal third quarter with 26 million in cash and cash equivalents that are expected to fund its work into the first calendar quarter of 2023, including advancing the companys ophthalmic formulation of bevacizumab towards US Food and Drug Administration FDA approval. In reporting its financial results for the three months ended June 30, 2022, the company highlighted a number of recent corporate milestones, including confirming its plans to re-submit a Biologics License Application BLA for ONS-5010 for the treatment of wet age-related macular degeneration wet AMD to the US FDA by September 2022. 